Daniel Abankwa

This study shows K-Ras4B sustains ciliation during muscle cell differentiation by localizing to the primary cilium, affecting asymmetric cell divisions and differentiation outcomes.

This study investigates how KRAS regulates de- and re-ciliation in muscle stem- and progenitor cells through interactions with CEP55, Aurora kinase A, and the PDE6D trafficking pathway.

This study develops a genetically encoded PDE6D inhibitor, SNAP-STI, which shows higher potency than small molecule inhibitors but does not effectively inhibit K-Ras membrane anchorage or MAPK signaling.

The paper identifies SPRY2 as a novel K-Ras effector that impacts its membrane organisation through proteomics and BRET screens.

The paper provides a BRET protocol to measure and analyze transient protein interactions of K-RasG12V in HEK293-EBNA cells.

The paper identifies a peptide that disrupts the interaction between Gal1 and B-Raf-RBD, reducing H-Ras nanoclustering and MAPK signaling in cancer cells.

This study investigates how RAS isoform mutations affect cell differentiation using C2C12 myoblasts, finding distinct roles for K-Ras, N-Ras, and H-Ras and differential effects of pathway drugs.

The paper develops a novel PDE6D inhibitor, Deltaflexin3, which synergizes with Sildenafil to inhibit KRAS mutant cancer cell growth, though survival data suggest further exploration of K-Ras and PDE6D interplay.

The paper develops a pharmacophore model for SARS-CoV-2 3CLpro inhibitors and validates computationally screened compounds experimentally.